

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 14, 2025

Financial Results for the Three Months Ended September 30, 2025 (Japanese Accounting Standards)

Company name: TAUNS Laboratories, Inc.
 Listing: Tokyo Stock Exchange
 Securities code: 197A
 URL: <https://www.tauns.co.jp/>
 Representative: Masaki Nonaka, President and CEO
 Contact person: Yoshio Uchiyama, Director and CFO
 Telephone: +81-55-953-9590
 Scheduled date of payment of cash dividends: —
 The additional material of the Financial Results: Yes
 The briefing session of the Financial Results: No

(Amounts less than one million yen are rounded down.)

1. Financial Results for the Three Months Ended September 30, 2025 (July 1, 2025 - September 30, 2025)

(1) Operating results (Percent indications show percentage of changes from corresponding figures for the previous period)

	Net sales		Operating income		Ordinary income		Net income	
Three Months Ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2025	2,368	(63.1)	547	(85.4)	505	(86.5)	357	(86.7)
September 30, 2024	6,419	—	3,745	—	3,753	—	2,696	—

	Basic earnings per share	Diluted earnings per share
Three Months Ended	Yen	Yen
September 30, 2025	3.47	3.33
September 30, 2024	26.82	25.20

Note: No financial results for the three months ended September 30, 2023 being prepared, the increase/decrease ratio for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 is not presented.

(2) Financial position

	Total assets	Net assets	Net assets as a percentage of total assets
	Millions of yen	Millions of yen	%
FY2026 1 st quarter	39,084	15,518	39.7
FY2025	36,515	17,417	47.7

Reference: Net assets excluding share subscription rights: 15,513 million yen as of September 30, 2025
 17,412 million yen as of June 30, 2025

2. Dividends

	Annual cash dividends per share				
	At 1st quarter end	At 2nd quarter end	At 3rd quarter end	At fiscal year end	Total
	yen	yen	yen	yen	yen
FY2025	—	6.00	—	22.00	28.00
FY2026	—				
FY2026 (Forecast)		14.00	—	14.00	28.00

Note: 1. Changes in dividends forecast for FY2025 from the latest disclosure: Yes
 2. The year-end dividends for FY2025 include special dividend of 10.00 yen.
 3. For details regarding the revision of the dividend forecast, please refer to the 'Notice of Revision of Dividend Forecast' published today (14 November 2025).

3. Forecast of operating results for FY2026 (July 1, 2025 - June 30, 2026)

(Indications show percentage of changes from corresponding figures for the previous period)

	Net sales		Operating income		Ordinary income		Net income		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	yen
FY2026	20,769	11.5	8,323	0.7	8,143	(0.9)	8,613	36.4	84.66

Note 1. Changes in forecast of operating results for FY 2026 from the latest disclosure: No

2. Forecast for operating results for FY2026 1st half is not prepared.

※ Notes

(1) Adoption of specific accounting policies for quarterly financial statements: Yes

Note: See attached page 7 (3) Notes to quarterly financial statements – (Notes to adoption of specific accounting policies for quarterly financial statements)

(2) Changes in accounting policies, accounting estimation change and restatement

① Changes in accounting policies due to the revision of the accounting standards : None

② Changes in accounting policies except for those in ① : None

③ Changes due to accounting estimation change : None

④ Restatement : None

(3) Number of shares issued (common shares)

① Number of shares issued at the fiscal year end (including treasury stocks)

② Number of treasury stocks at the fiscal year end

③ The average number of shares issued during the fiscal year

FY2026 1st quarter	103,211,774 shares	FY2025	102,992,370 shares
FY2026 1st quarter	— shares	FY2025	— shares
FY2026 1st quarter	103,178,998 shares	FY2024 1 st quarter	100,533,960 shares

※ Review by external auditor: None

※ Explanation regarding the appropriate use of forecast of business results

The financial forecast is based on judgments and estimates that have been made on the basis of currently available information. By nature, such financial forecast is subject to uncertainty and risk. Therefore, you are advised that the final results might be significantly different from the aforementioned forecast due to changes in economic environments related to our business, market trends and exchange rate, etc.

Please refer to “1. Overview of the operating results, etc., (3) Explanation on financial forecast” on page 3 for the assumptions used in forecasting business results and precautions regarding the use of business results forecasts.

○Table of content of material

1. Overview of the operating results, etc.	4
(1) Overview of business performance for the current quarter	4
(2) Overview of financial position for the current quarter	4
(3) Explanation on financial forecast	5
2. Financial Statements	6
(1) Balance sheet	6
(2) Statement of income	8
(3) Notes to quarterly financial statements	9
Notes to adoption of specific accounting policies for quarterly financial statements	9
Notes to business segments and related information	9
Notes to significant changes in shareholders' equity	9
Notes to events and conditions which indicate there could be substantial doubt about going concern assumption	9
Notes to quarterly cash flow statements	9

1. Overview of the operating results, etc.

(1) Overview of business performance for the current quarter

Regarding the business environment for the in vitro diagnostic medical device industry during the first quarter period (July 1, 2025 to September 30, 2025), although the 13th wave of COVID-19 peaked in the first half of August 2025, its scale remained low compared to the 11th wave during the same period last year. Consequently, demand for antigen test kits decreased compared to the same period last year. Furthermore, the phase of reducing the market inventory of antigen test kits secured by wholesalers during the previous epidemic period continued from the fourth quarter of the previous fiscal year until around the end of this first quarter, which also contributed to the decline in sales for this first quarter.

As a result, for the first quarter cumulative period, net sales were ¥2,368 million (63.1% decrease compared to the first quarter of the previous year), operating income was ¥547 million (85.4% decrease in the same), ordinary income was ¥505 million (86.5% decrease in the same), and net income was ¥357 million (86.7% decrease in the same).

<Net sales trend> (Unit: millions of yen)

	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	Total
FY2024	6,943	4,673	4,754	2,063	18,434
FY2025	6,419	5,561	5,626	1,020	18,627
FY2026	2,368	—	—	—	—

Regarding quarterly sales trends, while first quarter sales were at a high level in previous years, However, for the current period, sales in the first quarter decreased compared to previous years. This was due to the lower prevalence of major respiratory infectious diseases compared to previous years, as well as the fact that the phase of reducing the market inventory of antigen test kits secured by wholesalers in the third quarter of the previous year continued from the fourth quarter of the previous year until around the end of the first quarter of the current year.

<1st Quarter P/L Comparison> (Unit: millions of yen)

	FY2024 1Q	FY2025 1Q	FY2026 1Q	Increase/(decrease)
Net sales	6,943	6,419	2,368	(63.1%)
Gross profit	4,802	4,810	1,630	(66.1%)
Gross profit ratio (%)	69.2%	74.9%	68.8%	(6.1%)
Operating income	3,746	3,745	547	(85.4%)
Operating income ratio (%)	53.9%	58.3%	23.1%	(35.2%)
Ordinary income	3,741	3,753	505	(86.5%)
Ordinary income ratio (%)	53.9%	58.5%	21.3%	(37.1%)
Net income	2,685	2,696	357	(86.7%)
Net income ratio (%)	38.7%	42.0%	15.1%	(26.9%)

For the first quarter, operating income, ordinary income, and quarterly net income all decreased due to a decline in net sales.

<Sales by main product in the first quarter> (Unit: millions of yen)

Sales by main product	FY2024 1st Quarter (a)	FY2025 1st Quarter (b)	FY2026 1st Quarter (c)	(c) / (b)
COVID-19 single-use test kits	2,374	3,284	1,229	(62.6%)
Influenza/COVID-19 combo test kits	2,479	2,013	374	(81.4%)
Influenza test kits	1,286	400	179	(55.2%)
Others	803	720	584	(18.9%)
Total	6,943	6,419	2,368	(63.1%)

Sales by main product category fell below the same period last year across the board. This was due to the fact that, while the 13th wave of COVID-19 occurred during the first quarter of the current year, the overall prevalence of respiratory infections remained low. Furthermore, the phase of reducing market inventories continued. This contrasted with the first quarter of the previous year, when demand for COVID-19 single-use test kits surged due to the arrival of the 11th wave of COVID-19 infections.

(2) Overview of financial position for the current quarter

Total assets at the end of the first quarter of the current year increased by ¥2,568 million compared to the end of the previous year, reaching ¥39,084 million. This was primarily due to a significant increase in accounts receivable and construction in progress related to the new factory construction, despite a decrease in cash and deposits.

Total liabilities increased by ¥4,468 million compared to the end of the previous year, reaching ¥23,565 million. This was

primarily due to an increase in long-term borrowings related to the construction of a new factory, despite a decrease in income taxes payable associated with the payment of tax expenses.

Total net assets decreased by ¥1,899 million compared to the end of the previous year, reaching ¥15,518 million. This was primarily due to a decrease in retained earnings resulting from the payment of dividends.

(3) Explanation on financial forecast

Regarding the full-year earnings forecast for the fiscal year ending June 2026, although sales for the first quarter fell below the same period last year, the phase of reducing market inventory for antigen test kits has ended. Furthermore, influenza entered its epidemic season earlier than usual, starting in late September. Consequently, demand for antigen test kits is currently increasing. Based on these factors, we are maintaining the earnings forecast announced on August 13, 2025.

2. Financial Statements

(1) Balance sheet

(Unit: thousands of yen)

	Prior fiscal year (As of June 30, 2025)	Current first quarter (As of September 30, 2025)
Assets		
Current assets		
Cash on hand and in banks	9,266,630	4,609,929
Accounts receivable – trade	247,777	2,315,071
Merchandise and finished goods	3,043,200	3,872,754
Work in process	1,515,674	1,638,527
Raw materials and supplies	1,324,652	1,300,286
Other	78,670	1,126,905
Total current assets	15,476,605	14,863,475
Fixed assets		
Property, plant and equipment		
Construction in progress	8,213,450	11,395,924
Other	4,065,762	4,068,885
Total property, plant and equipment	12,279,213	15,464,810
Intangible fixed assets		
Customer related assets	2,499,200	2,442,400
Technology related assets	596,800	571,933
Other	740,768	827,412
Total of intangible fixed assets	3,836,768	3,841,746
Investments and other assets		
Investment securities	4,177,271	4,177,015
Other	745,435	737,016
Total investments and other assets	4,922,707	4,914,032
Total fixed assets	21,038,688	24,220,588
Total assets	36,515,294	39,084,063

(Unit: thousands of yen)

	Prior fiscal year (As of June 30, 2025)	Current first quarter (As of September 30, 2025)
Liabilities		
Current liabilities		
Accounts payable – trade	1,199,041	1,298,136
Short-term borrowings	4,500,000	4,500,000
Current portion of long-term borrowings	1,114,919	1,695,223
Accrued income taxes	842,289	161,958
Allowance for bonuses	153,612	254,682
Allowance for bonuses to directors	17,791	—
Other	1,702,221	1,577,957
Total current liabilities	9,529,874	9,487,958
Long-term liabilities		
Long-term borrowings	8,809,081	13,313,880
Deferred tax liabilities	556,304	556,100
Accrued retirement benefits	190,363	195,740
Asset retirement obligations	12,000	12,000
Total long-term liabilities	9,567,749	14,077,721
Total liabilities	19,097,624	23,565,679
Net assets		
Shareholders' equity		
Common stock	289,771	296,353
Deposits for subscriptions rights to common stocks	7,913	4,072
Capital surplus	2,773,071	2,779,653
Retained earnings	14,307,551	12,399,621
Total shareholders' equity	17,378,307	15,479,700
Valuation and translation adjustments		
Net unrealized gains (losses) on available-for-sale securities	34,452	33,993
Total valuation and translation adjustments	34,452	33,993
Share subscription rights	4,910	4,689
Total net assets	17,417,670	15,518,383
Total liabilities and net assets	36,515,294	39,084,063

(2) Statement of income

(Unit: thousands of yen)

	Prior first quarter (From July 1, 2024 To September 30, 2024)	Current first quarter (From July 1, 2025 To September 30, 2025)
Net sales	6,419,625	2,368,410
Cost of sales	1,608,798	738,403
Gross profit	4,810,827	1,630,007
Selling, general and administrative expenses	1,065,622	1,082,484
Operating income	3,745,205	547,522
Non-operating income		
Interest income	1,398	8,450
Dividends income	110	126
Subsidy income	22,468	—
Miscellaneous income	475	198
Total non-operating income	24,452	8,774
Non-operating expenses		
Interest expenses	15,779	50,750
Miscellaneous expenses	40	217
Total non-operating expenses	15,819	50,968
Ordinary income	3,753,838	505,329
Special gains		
Gain on sales of fixed assets	1,448	855
Gain on reversal of subscription rights to stocks	3	2
Total special gains	1,451	857
Special losses		
Loss on disposal of fixed assets	—	0
Total special losses	—	0
Income before income taxes	3,755,290	506,187
Income taxes	1,058,603	148,284
Net income	2,696,686	357,902

(3) Notes to quarterly financial statements

(Notes to adoption of specific accounting policies for quarterly financial statements)

(Calculation of tax expense)

Income taxes are determined based on the amount of income before income taxes for the current first quarter ended September 30, 2025 multiplied by the effective tax rate, after adoption of tax-effect accounting, estimated for the entire fiscal year ending June 30, 2026.

(Notes to business segments and related information)

【Business segments information】

I Prior first quarter (From July 1, 2024 to September 30, 2024)

No segment information is provided as the Company has only one segment, which is IVD (in vitro diagnostics) business.

II Current first quarter (From July 1, 2025 to September 30, 2025)

No segment information is provided as the Company has only one segment, which is IVD (in vitro diagnostics) business.

(Notes to significant changes in shareholders' equity)

None

(Notes to events and conditions which indicate there could be substantial doubt about going concern assumption)

None

(Notes to quarterly cash flow statements)

Quarterly cash flow statements are not prepared for the current first quarter. The amount of depreciation including both tangible assets and intangible assets for the current first quarter is as follows:

	Prior first quarter (From July 1, 2024 To September 30, 2024)	Current first quarter (From July 1, 2025 To September 30, 2025)
Depreciation	171,968 thousands of yen	182,437 thousands of yen

